ProCE Banner Activity


Advances in Immunotherapy for Earlier Stages of Cancer: Guidance for Community Multidisciplinary Teams


Watch this on-demand webcast from a live webinar on the role of immune checkpoint inhibitors in early stages of cancer.

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: July 24, 2023

Expiration: July 23, 2024



Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Patrick Forde

Patrick Forde, MBBCh

Director, Thoracic Oncology Research Program
Oncology Department
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

This program is intended for multidisciplinary teams consisting of medical oncologists, radiation oncologists, thoracic oncologists, pulmonologists, surgeons, nurses, pharmacists, and other community healthcare professionals involved in the neoadjuvant or adjuvant treatment of patients with early-stage cancer.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in understanding and applying the latest science and clinical trial data on current and emerging immuno-oncology therapies in earlier stages of cancer into clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the biologic rationale for the use of immuno-oncology in earlier stages of cancer, considering the available clinical data, impact on tumor natural history, and immune-related implications.

  • Evaluate clinical trial data and endpoints, including survival surrogates, on the use of immune checkpoint inhibitors as neoadjuvant/adjuvant therapy to inform patients earlier stages of cancer on the potential long-term benefits of this therapeutic strategy

  • Identify patients with early-stage solid cancers who would be appropriate for treatment or clinical trial enrollment with immune checkpoint inhibitors in the neoadjuvant, adjuvant, or maintenance/consolidation setting based on recurrence risk, surgical considerations, biomarkers, risk–benefit considerations, as well as potential disparities (socio-economic, racial, and age) in care

  • Identify and manage common and serious immune-related adverse events associated with immuno-oncology agents in early stages of cancer


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Patrick Forde, MBBCh

Director, Thoracic Oncology Research Program
Oncology Department
Johns Hopkins University
Baltimore, Maryland

Patrick Forde, MBBCh: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, F Star, G1 Therapeutics, Genentech, Gritstone, iTeos, Janssen, Novartis, Regeneron, Sanofi, Surface, Synthekine; researcher: AstraZeneca, BioNTech, Bristol Myers Squibb, Novartis, Regeneron.

Program Director

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur MD, MPH: consultant/advisor: AstraZeneca, Crown Bioscience, Daiichi Sankyo, Gilead, Immunomedics, Merck, Pfizer, Puma, Seattle Genetics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose. 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 24, 2023, through July 23, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-189-H01-P 
Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.